

# MARKET REPORT



Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021

IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases. In addition, there has been a substantial increase in IVIG prescriptions for the treatment of off-label indications, such as, specific antibody deficiency, Guillain-Barre syndrome, Inflammatory Myopathies and others. However, factors such as the high cost of IVIG treatment, side effects associated with use of IVIG, stringent government regulations and a lengthy product approval process would hamper its market growth. Despite several challenges such as inadequate supply of immunoglobulins, stringent regulatory policies and the high cost associated with IVIG treatments, the global IVIG market would witness notable growth during the forecast period. Global IVIG market is segmented based on its types, application and geography. The application segment includes Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukaemia (CLL), Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barre syndrome, and others.

Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP) holds a dominant share in the market due to a large patient population and the unavailability of effective alternatives for IVIG treatment. Geographically, the report covers five key regions, North America, Europe, Asia Pacific, and LAMEA. Presently, North America occupies a majority of the market followed by the Asia Pacific region. High adoption of IVIG therapies and a large pool of patient population in the North American region is a prime factor responsible for the growth of the North America IVIG market. However, in the Asia-pacific region, growing awareness for immunodeficiency disease & neurological disorders along with the increasing preference towards IVIG therapies, largely drives the market. The companies profiled in this report include Baxter international Inc., CSL Limited, Grifols S.A, Octapharma Ag, Kedrion Pharma, LFB group, Biotest AG, china Biologics products Ltd, Bayer Healthcare, and others. A comprehensive analysis of factors that drive and restrict the growth of the Global IVIG market. For instance, a large patient population and favorable government regulations will drive the Global IVIG market; however, the high cost of IVIG treatment and the associated risk of infection is likely to be a major restraint for the market. The projections in the report are made by analyzing the current market trends and market potential for the period of 2014-2021, in terms of volume and value. The report covers a comprehensive analysis of all the geographic regions that help in determining the prevailing opportunities in these geographies. Government regulations regarding IVIG production and purification are discussed in detail. Competitive intelligence (of leading manufacturers of IVIG) helps in understanding the market scenario across geographies. SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companies. The report provides a quantitative analysis of the current market and estimations through 2014-2021 that help in identifying the prevailing market opportunities.

**KEY MARKET SEGMENT:** Global IVIG market is segmented based on the application, types and geography.

**MARKET BY APPLICATION:** Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukaemia (CLL), Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barre syndrome, Others.

**MARKET BY TYPE:** IgG, IgA, IgM, IgE, D.

**MARKET BY GEOGRAPHY:** North America (United States, Canada, Mexico), Europe (Germany, France, United Kingdom, Russia, Austria, Italy, Others), Asia-Pacific (India, China, Japan, Australia, Others), LAMEA (Latin America, Middle East, Africa).

## Additional Details

**Publisher :** Allied Market Research

**Reference :** LI 16325

**Number of Pages :** 131

**Report Format :** PDF

**Publisher Information :**



**Allied Market Research**  
Diligent Intelligence - Improved Growth

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021 [Report Updated: 01-12-2016]

- TABLE OF CONTENTS

## CHAPTER 1 INTRODUCTION

- 1.1 Report description
- 1.2 Key benefits
- 1.3 Key market segment
- 1.4 Research methodology
  - 1.4.1 Secondary Research
  - 1.4.2 Primary Research
  - 1.4.3 Analyst tools and models

## CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 CXO perspective
- 2.2 Market beyond what to expect by 2026 (\$Million)
  - 2.2.1 Moderate growth scenario
  - 2.2.2 Rapid growth scenario
  - 2.2.3 Diminishing growth scenario

## CHAPTER 3 MARKET OVERVIEW

- 3.1 Market definition and scope
- 3.2 Overview of Intravenous Immunoglobulin (IVIg)
  - 3.2.1 Patented products
- 3.3 Epidemiology and economic burden of chronic conditions
- 3.4 Cost of side effects due to IVIg treatments
- 3.5 Key findings
  - 3.5.1 Top Factors Impacting global intravenous immunoglobulin market
  - 3.5.2 Top Investment pockets - Global Intravenous Immunoglobulin Market
- 3.6 Porter's five forces analysis
  - 3.6.1 Bargaining power of buyers (Low)
  - 3.6.2 Bargaining power of suppliers (Low)
  - 3.6.3 Threat of new entrants (low)
  - 3.6.4 Threat of substitutes (low)
  - 3.6.5 Intense competitive rivalry (moderate)

### 3.7 Value chain analysis

#### 3.7.1 Primary activities

#### 3.7.2 Support Activities

### 3.8 Market share analysis (2014)

#### 3.9 Product scenario in IVIG market

#### 3.10 Government regulations and reimbursements

##### 3.10.1 Intravenous Immunoglobulin (IVIG) regulations in United States and Europe

##### 3.10.2 Reimbursements Scenario

#### 3.11 Indications for IVIG

##### 3.11.1 USFDA Indications

##### 3.11.2 European Medicine Agency

#### 3.12 Component analysis of intravenous immunoglobulins (IgG)

##### 3.12.1 IgG1

##### 3.12.2 IgG2

##### 3.12.3 IgG3

##### 3.12.4 IgG4

#### 3.13 Clinical trials

#### 3.14 Patent analysis of IVIG market (2011-2014)

##### 3.14.1 Patent analysis by geography

##### 3.14.2 U.S. patent analysis

##### 3.14.3 Europe Patent Analysis

#### 3.15 Market dynamics

##### 3.15.1 Drivers

###### 3.15.1.1 Rising Number of immunodeficiency Deficiency

###### 3.15.1.2 Increase in adoption of IVIG

###### 3.15.1.3 Increasing Number of People with Bleeding Disorders

###### 3.15.1.4 Rising Ageing Population

##### 3.15.2 Restraints

###### 3.15.2.1 Stringent Regulations

###### 3.15.2.2 High Cost of Therapy

##### 3.15.3 Opportunities

###### 3.15.3.1 Opportunities in emerging economies

###### 3.15.3.2 Development of cost effective therapeutics through large scale production

## CHAPTER 4 GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021

### 4.1 Hypogammaglobulinemia

### 4.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

#### 4.1 Immunodeficiency diseases

#### 4.2 Congenital AIDS

- 4.3 Chronic Lymphocytic Leukemia
- 4.4 Myasthenia Gravis
- 4.5 Multifocal motor neuropathy
- 4.6 Primary Immune thrombocytopenia (ITP)
- 4.7 Kawasaki disease
- 4.8 Guillain-Barre syndrome
- 4.9 Others

## CHAPTER 5 GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET BY PRODUCT TYPES

### 5.1 IgG

- 5.1.1 Key Market Trends
- 5.1.2 Clinical Interpretations

### 5.2 IgA

- 5.2.1 Key Market Trends
- 5.2.2 Clinical interpretation

### 5.3 IgM

- 5.3.1 Key Market Trends
- 5.3.2 Clinical Interpretation

### 5.4 IgE

- 5.4.1 Key Market Trends
- 5.4.2 Clinical Interpretation

### 5.5 IgD

- 5.5.1 Key Market Trends

## CHAPTER 6 GLOBAL IVIG MARKET, BY GEOGRAPHY, 2014-2021

### 6.1.1 Market size and forecast

### 6.2 North America

#### 6.2.1 U.S.

- 6.2.1.1 Key Market Trends
- 6.2.1.2 Market size and forecast

#### 6.2.2 Canada

- 6.2.2.1 Key Market Trends
- 6.2.2.2 Market size and forecast
- 6.2.2.3 Mexico
- 6.2.2.4 Key Market Trends
- 6.2.2.5 Market Size and forecast

### 6.3 Europe

- 6.3.1 Key market trends

6.3.2 Market size and forecast

6.3.3 U.K.

6.3.3.1 Key Market Trend

6.3.3.2 Market size and forecast

6.3.4 France

6.3.4.1 Key market trends

6.3.4.2 Market size and forecast

6.3.5 Germany

6.3.5.1 Market size and forecast

6.3.6 Italy

6.3.6.1 Market size and forecast

6.3.7 Austria

6.3.7.1 market size and forecast

6.3.8 Russia

6.3.8.1 market size and forecast

6.4 Asia-Pacific

6.4.1 Key market trends

6.4.2 Market size and forecast

6.4.3 Australia

6.4.3.1 Market size and forecast

6.4.4 Japan

6.4.4.1 Market size and forecast

6.4.5 India

6.4.5.1 Market size and forecast

6.4.6 China

6.4.6.1 Market size and forecast

6.4.7 Others

6.4.7.1 Market size and forecast

6.5 LAMEA

6.5.1 Key Market Trends

6.5.2 Market size and forecast

6.5.3 Latin America



6.5.3.1 Market size and forecast

6.5.4 Middle East

6.5.4.1 Market size and forecast

6.5.5 Africa

6.5.5.1 Market size and forecast

## CHAPTER 7 COMPANY PROFILES

7.1 Biotest AG

7.1.1 Company overview

7.1.2 Biotest AG snapshot

7.1.3 Operating business segment overview

7.1.4 Financial performance

7.1.5 Strategic moves and developments

7.1.6 SWOT analysis of Biotest AG

7.2 Octapharma AG

7.2.1 Company overview

7.2.2 Octapharma AG snapshot

7.2.3 Operating business segment overview

7.2.4 Strategic moves and developments

7.2.5 SWOT analysis of Octapharma AG

7.3 Baxter International Inc.

7.3.1 Company overview

7.3.2 Baxter International Inc. snapshot

7.3.3 Operating business segments overview

7.3.4 Financial performance

7.3.5 Strategic moves and developments

7.3.6 SWOT analysis of Baxter International Inc.

7.4 LFB Biotechnologies

7.4.1 Company overview

7.4.2 LFB Biotechnologies snapshot

7.4.3 Operating business segment overview

7.4.4 Financial performance

7.4.5 SWOT analysis of LFB biotechnologies

7.5 China Biologics Products Inc.

7.5.1 Company overview

7.5.2 China Biologic Products Inc. Snapshot

7.5.3 Operating business segment overview

7.5.4 Financial performance

7.5.5 Strategic moves and developments

7.5.6 SWOT analysis of China Biologic Products Inc.

7.6 Grifols S.A.

- 7.6.1 Company overview
- 7.6.2 Grifols S.A Snapshot
- 7.6.3 Operating Business Segment Overview
- 7.6.4 Financial performance
- 7.6.5 Strategic moves and developments
- 7.6.6 SWOT analysis Grifols S.A.

## 7.7 Kedrion Biopharma

- 7.7.1 Company overview
- 7.7.2 Kedrion Biopharma. Snapshot
- 7.7.3 Operating business segment overview
- 7.7.4 Financial performance
- 7.7.5 Strategic moves and developments
- 7.7.6 SWOT Analysis of Kedrion Biopharma.

## 7.8 CSL Behring

- 7.8.1 Company overview
- 7.8.2 CSL Behring Snapshot
- 7.8.3 Operating business segment overview
- 7.8.4 Financial performance
- 7.8.5 Strategic moves and developments
- 7.8.6 SWOT ANALYSIS of CSL Behring

## 7.9 BDI Pharma Inc.

- 7.9.1 Company overview
- 7.9.2 BDI pharma Inc. Snapshot
- 7.9.3 Operating business segment overview
- 7.9.4 SWOT Analysis of BDI Pharma

## 7.10 Bayer Healthcare

- 7.10.1 Company overview
- 7.10.2 Business performance
- 7.10.3 Strategic moves and developments
- 7.10.4 SWOT analysis of Bayer Healthcare

## LIST OF TABLES

- TABLE 1 MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (\$MILLION)
- TABLE 2 MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (TONNE)
- TABLE 3 RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (\$MILLION)
- TABLE 4 RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (TONNE)
- TABLE 5 DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (\$MILLION)
- TABLE 6 DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (TONNE)
- TABLE 7 IVIG PRODUCTS COMMERCIALIZED IN MARKET
- TABLE 8 USFDA INDICATIONS FOR IVIG
- TABLE 9 EMA APPROVED INDICATIONS FOR IVIG
- TABLE 10 IGG SUBCLASS
- TABLE 11 FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
- TABLE 12 DISEASE ASSOCIATE WITH IGG SUBCLASS DEFICIENCY
- TABLE 13 CLINICAL TRIALS FOR INTRAVENOUS IMMUNOGLOBULIN (2011-2014)
- TABLE 14 PATENT ANALYSIS- UNITED STATES (2010-2014)
- TABLE 15 PATENT ANALYSIS- EUROPE (2010-2014)

TABLE 16 WORLD AGING POPULATION 2013

TABLE 17 GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021, \$MILLION

TABLE 18 GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021, (TONNE)

TABLE 19 COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS

TABLE 20 HYPOGAMMAGLOBULINEMIA IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 21 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 22 PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY

TABLE 23 IMMUNODEFICIENCY DISEASES IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 24 IVIG PRODUCTS FOR CONGENITAL AIDS

TABLE 25 CONGENITAL AIDS IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 26 CLL STATISTICS 2011-2014

TABLE 27 CHRONIC LYMPHOCYTIC LEUKAEMIA IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 28 MYASTHENIA GRAVIS IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 29 MULTIFOCAL MOTOR NEUROPATHY IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 30 ITP TREATMENT OPTIONS

TABLE 31 ITP IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 32 KAWASAKI DISEASE PATIENTS PER 100,000 CHILDREN IN 2010

TABLE 33 KAWASAKI DISEASE IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 34 GUILLAIN-BARRE SYNDROME IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 35 OTHER IVIG APPLICATION MARKET (\$MILLION & TONNE), 2014-2021

TABLE 36 GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, (\$MILLION)

TABLE 37 GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, (TONNE)

TABLE 38 NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, (\$ MILLION)

TABLE 39 NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)

TABLE 40 EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, (\$ MILLION)

TABLE 41 EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)

TABLE 42 HIGH PRIORITY INDICATIONS OF IVIG

TABLE 43 COST OF IVIG PRODUCTS IN UK

TABLE 44 PRODUCTS CONTAINING IVIG IN ITALIAN MARKET

TABLE 45 ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, (\$MILLION)

TABLE 46 ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)

TABLE 47 IMMUNOGLOBULIN BRANDS AND ITS MANUFACTURERS

TABLE 48 LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, (\$ MILLION)

TABLE 49 LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)

TABLE 50 BIOTEST AG SANPSHOT

TABLE 51 OPERATING BUSINESS SEGMENT OVERVIEW

TABLE 52 OCTAPHARMA AG SNAPSHOT

TABLE 53 OCTAPHARMA AG OPERATING BUSNIESS OVERVIEW

TABLE 54 BAXTER INTERNATIONAL INC. SNAPSHOT

TABLE 55 OPERATING BUSINESS SEGMENTS OVERVIEW

TABLE 56 LFB BIOTECHNOLOGIES OPERATING SEGMENT OVERVIEW

TABLE 57 CHINA BIOLOGIC PRODUCTS INC. SNAPSHOT

TABLE 58 CHINA BIOLOGIC PRODUCTS INC. OPERATING BUSINESS SEGMENT OVERVIEW

TABLE 59 GRIFOLS S.A SNAPSHOT

TABLE 60 GRIFOLS S.A OPERATING SEGEMENTS

TABLE 61 KEDRION INC. SNAPSHOT

TABLE 62 KEDRION BIOPHARMA OPERATING SEGMENTS

TABLE 63 CSL BEHRING SNAPSHOT

TABLE 64 CSL BEHRING OPERATING SEGMENTS

TABLE 65 BDI PHARMA INC SNAPSHOT

TABLE 66 BDI PHARMA OPERATING SEGMENTS

TABLE 67 BAYER HEALTHCARE COMPANY SNAPSHOT

## LIST OF FIGURES

FIG. 1 IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN MODERATE GROWTH SCENARIO  
 FIG. 2 IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN RAPID GROWTH SCENARIO  
 FIG. 3 IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN DIMINISHING GROWTH SCENARIO  
 FIG. 4 PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY  
 FIG. 5 TOP FACTORS IMPACTING GLOBAL IVIG MARKET (2015-2021)  
 FIG. 6 TOP INVESTMENT POCKETS - GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET  
 FIG. 7 PORTER'S FIVE FORCES ANALYSIS  
 FIG. 8 VALUE CHAIN ANALYSIS OF GLOBAL IVIG MARKET  
 FIG. 9 MARKET SHARE ANALYSIS - GLOBAL IVIG MARKET 2014  
 FIG. 10 PATENT ANALYSIS BY GEOGRAPHY (2011-2014)  
 FIG. 11 U.S. PATENT ANALYSIS BY COMPANY (2011-2014)  
 FIG. 12 EUROPE PATENT ANALYSIS, BY COMPANY (2011-2014)  
 FIG. 13 INCIDENCES OF HAEMOPHILIA, 2010  
 FIG. 14 BIOTEST AG FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)  
 FIG. 15 BIOTEST AG FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)  
 FIG. 16 SWOT ANALYSIS OF BIOTEST AG  
 FIG. 17 SWOT ANALYSIS OF OCTAPHARMA AG  
 FIG. 18 BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)  
 FIG. 19 BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)  
 FIG. 20 SWOT ANALYSIS OF BAXTER INTERNATIONAL INC  
 FIG. 21 LFB BIOTECHNOLOGIES FINANCIAL PERFORMANCE BY PRODUCT SEGMENT (2013)  
 FIG. 22 LFB BIOTECHNOLOGIES FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)  
 FIG. 23 SWOT ANALYSIS OF LFB BIOTECHNOLOGIES  
 FIG. 24 CHINA BIOLOGIC PRODUCTS INC. FINANCIAL PERFORMANCE BY SEGMENTS  
 FIG. 25 SWOT ANALYSIS OF CHINA BIOLOGIC PRODUCTS INC.  
 FIG. 26 FINANCIAL OF GRIFOLS S.A BY GEOGRAPHY (2013)  
 FIG. 27 FINANCIAL GRIFOLS S.A. BY PRODUCT GROUPS (2013)  
 FIG. 28 SWOT ANALYSIS OF GRIFOLS S.A.  
 FIG. 29 FINANCIAL REVENUE OF KEDRION BIOPHARMA GEOGRAPHY (2013)  
 FIG. 30 FINANCIAL KEDRION BIOPHARMA. BY PRODUCT GROUPS (2013)  
 FIG. 31 SWOT ANALYSIS OF KEDRION BIOPHARMA  
 FIG. 32 CSL BEHRING FINANCIAL REVENUE OF BY GEOGRAPHY (2013)  
 FIG. 33 CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)  
 FIG. 34 SWOT ANALYSIS OF CSL BEHRING  
 FIG. 35 SWOT ANALYSIS OF BDI PHARMA  
 FIG. 36 FINANCIAL REVENUE OF BAYER HEALTHCARE (2013 AND 2012)  
 FIG. 37 FINANCIALS OF BAYER HEALTHCARE, BY SEGMENTS, 2013  
 FIG. 38 SWOT ANALYSIS OF BAYER HEALTHCARE

# How to Buy...

Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021 [Report Updated: 01-12-2016]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/103378>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$5370** | Single User Price
- \$5910** | Five User License Price
- \$7800** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.